Dataset Information

Review of the Omnipod^® 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes.

ABSTRACT: Type 1 diabetes (T1D) is a medical condition that requires constant management, including monitoring of blood glucose levels and administration of insulin. Advancements in diabetes technology have offered methods to reduce the burden on people with T1D. Several hybrid closed-loop systems are commercially available or in clinical trials, each with unique features to improve care for patients with T1D. This article reviews the Omnipod^® 5 Automated Glucose Control System Powered by Horizon™ and the safety and efficacy data to support its use in the management of T1D.

SUBMITTER: Cobry EC

PROVIDER: S-EPMC8097502 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Review of the Omnipod<sup>®</sup> 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes.

Cobry Erin C EC Berget Cari C Messer Laurel H LH Forlenza Gregory P GP

Therapeutic delivery 20200728 8

Type 1 diabetes (T1D) is a medical condition that requires constant management, including monitoring of blood glucose levels and administration of insulin. Advancements in diabetes technology have offered methods to reduce the burden on people with T1D. Several hybrid closed-loop systems are commercially available or in clinical trials, each with unique features to improve care for patients with T1D. This article reviews the Omnipod<sup>®</sup> 5 Automated Glucose Control System Powered by Horiz ...[more]

PMID: 32723002

Similar Datasets

Project description:ObjectiveThis prospective study assessed the efficacy of the Cochlear™ Osia® 2 System compared to the previous Baha® Attract System in patients with mixed or conductive hearing loss (MHL/CHL).MethodsIn this prospective case-control study, 10 patients (2 men and 8 women) with MHL/CHL were implanted with the Osia® 2 System. Their audiological outcomes were compared with 13 patients (2 men and 11 women) who had previously been implanted with the transcutaneous Baha® Attract system. We compared the complications and compliance of the two groups. Also, in the Osia 2 System group, subjective satisfaction was assessed using the Korean version of the International Outcome Inventory for Hearing Aids (K-IOI-HA) questionnaire and the Abbreviated Profile of Hearing Aid Benefit (APHAB) questionnaire.ResultsComplications such as poor magnetization, pain & infection, and abnormal noise were more common in the Baha Attract group, although not statistically significant. Also, the Osia 2 group exhibited better compliance. Subjective satisfaction was assessed using the K-IOI-HA and APHAB questionnaires with the Osia 2 group, revealing significantly improved scores in ease of communication, reverberation, background noise, and higher K-IOI-HA scores post-implantation. Postoperative-aided thresholds with both systems were significantly lower than preoperative-unaided thresholds, with the Osia 2 System demonstrating notably high satisfaction levels. Although both systems showed similar preoperative and postoperative word-recognition scores, the Osia 2 System provided greater audiological gain, especially at 2 kHz and 4 kHz frequencies. Additionally, the functional gain of both systems was comparable across all frequencies.ConclusionsThe Osia 2 System demonstrated high subjective satisfaction and improved audiological outcomes compared to the Baha Attract system in patients with conductive or mixed hearing loss. Its superior audiological gain, particularly at critical frequencies, along with better compliance, suggests it as a favorable option for this patient population.

Dataset Information

Review of the Omnipod^® 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes.

Publications

Review of the Omnipod<sup>®</sup> 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Review of the Omnipod® 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes.

Publications

Review of the Omnipod<sup>®</sup> 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Review of the Omnipod^® 5 Automated Glucose Control System Powered by Horizon™ for the treatment of Type 1 diabetes.